Please login to order a test.
Buprenorphine Medication Assisted Treatment Monitoring 2, Urine
- MAT Drug Screen
Detect and confirm presence of prescribed and illicit drugs for monitoring Suboxone™/buprenorphine medication assisted treatment (MAT). Please note: This testing is designed specifically for monitoring patients who are on Suboxone™/buprenorphine only. This testing should not be used for monitoring chronic pain patients (medical drug monitoring) or methadone medication assisted treatment.
Some components of this panel were developed, and performance characteristics determined, by LabCorp (EtG, Carisoprodol, Fentanyl, Tapentadol, and Gabapentin). They have not been cleared or approved by the US Food and Drug Administration (FDA).
Initial presumptive testing by immunoassay at the following testing thresholds: buprenorphine, 5 ng/mL; alcohol biomarkers (EtG, EtS), 500 ng/mL; amphetamines, 500 ng/mL; barbiturates, 200 ng/mL; benzodiazepines, 200 ng/mL; cocaine metabolite, 150 ng/mL; phencyclidine, 25 ng/mL; cannabinoids (THC), 20 ng/mL; heroin metabolite (6-AM), 10 ng/mL; opiates, 300 ng/mL; oxycodones, 100 ng/mL; tapentadol, 200 ng/mL; fentanyl, 2.0 ng/mL; methadone, 300 ng/mL; propoxyphene, 300 ng/mL; tramadol, 200 ng/mL; carisoprodol, 100 ng/mL; gabapentin, 1.5 μg/ml. Presumptive positives are confirmed by definitive mass spectrometry (LC/MS-MS or GC/MS).
Testing referred to MEDTOX Laboratories, Inc.
Room Temperature: 5 days
Causes for Rejection
Insufficient volume; no ID on container; urine from preservative tube